Context Therapeutics (CNTX) Q4 2025 earnings summary

Executive summary

• Advanced pipeline of T cell-engaging bispecific antibodies for solid tumors, with key clinical milestones expected in 2026.

• Presented early efficacy and safety data for CTIM-76 and preclinical data for CT-202 at major conferences.

• Cash runway projected to fund operations into mid-2027.

Financial highlights

• Cash and cash equivalents were $66.0 million at year-end 2025, down from $94.4 million at year-end 2024.

• Research and development expenses rose to $31.9 million in 2025 from $22.7 million in 2024, driven by increased spending on CT-202, CTIM-76, and personnel.

• General and administrative expenses increased to $7.8 million from $7.2 million year-over-year.

• Other income was $3.6 million, up from $3.2 million, mainly due to higher interest income.

• Net loss widened to $36.1 million in 2025 from $26.7 million in 2024.

Outlook and guidance

• Interim Phase 1a data for CTIM-76 expected in June 2026; for CT-95 in September 2026.

• First patient dosing for CT-202 Phase 1 trial anticipated in Q3 2026.

• Multiple clinical updates planned throughout 2026.

• Cash expected to fund operations into mid-2027.